ASCO 2022 | ZEN-3694, a novel BET inhibitor, in TNBC without germline BRCA1/2 mutations

Philippe Georges Aftimos, MD, Institut Jules Bordet, Brussels, Belgium, discusses results of a Phase Ib/II study (NCT03901469) evaluating ZEN-3694, a BET inhibitor, in combination with talazoparib for the treatment of patients with triple-negative breast cancer (TNBC) without germline BRCA1/2 mutations. The combination of ZEN-3694 and talazoparib demonstrated anti-cancer activity in pretreated patients with metastatic TNBC and wild-type gBRCA1/2. Dr Aftimos additionally describes efforts to create a new cohort of patients receiving sacituzumab govitecan, an antibody–drug conjugate (ADC) to further improve clinical outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.